CORT
Corcept Therapeutics Inc
Halal Rating :
Last Price
$55.30
Last updated:
Market Cap
-
7D Change
8.3%
1 Year Change
134.72%
Company Overview
Industries
Exchange
Next Earnings Date
Corcept Therapeutics Inc is a pharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Their lead product, Korlym® (mifepristone), was the first FDA-approved treatment for patients with Cushing's syndrome. The company also has a robust clinical development program investigating additional potential therapeutic applications for their proprietary selective cortisol modulators.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $182.55m | $135.95m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $163.8m | $128.2m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $146.81m | $117.31m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Corcept Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.